Eagle Pharmaceuticals Stock Today
| EGRX Stock | USD 4.55 0.22 4.61% |
Performance0 of 100
| Odds Of DistressLess than 2
|
Eagle Pharmaceuticals is trading at 4.55 as of the 25th of April 2024; that is -4.61 percent decrease since the beginning of the trading day. The stock's open price was 4.77. Eagle Pharmaceuticals has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Eagle Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of February 2014 | Category Healthcare | Classification Health Care |
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. Eagle Pharmaceuticals, Inc. The company has 12.96 M outstanding shares of which 1.21 M shares are currently shorted by private and institutional investors with about 9.63 trading days to cover. More on Eagle Pharmaceuticals
Moving against Eagle Stock
| 0.73 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.7 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.5 | ELYM | Eliem Therapeutics | PairCorr |
| 0.49 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Eagle Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eagle Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eagle Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Scott Tarriff | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Cancer Fighters, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Eagle Pharmaceuticals report their recommendations after researching Eagle Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Eagle Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Eagle Pharmaceuticals. The Eagle consensus assessment is calculated by taking the average forecast from all of the analysts covering Eagle Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Eagle Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eagle Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in May. Financial strength of Eagle Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Eagle Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eagle Pharmaceuticals' financial leverage. It provides some insight into what part of Eagle Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eagle Pharmaceuticals (EGRX) is traded on NASDAQ Exchange in USA. It is located in 50 Tice Boulevard, Woodcliff Lake, NJ, United States, 07677 and employs 134 people. Eagle Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 61.81 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eagle Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eagle Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eagle Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.96 M outstanding shares of which 1.21 M shares are currently shorted by private and institutional investors with about 9.63 trading days to cover.
Eagle Pharmaceuticals currently holds about 36.56 M in cash with 50.7 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.75.
Check Eagle Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationEagle Pharmaceuticals retains a total of 12.96 Million outstanding shares. The majority of Eagle Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eagle Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eagle Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eagle Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Note that regardless of who owns the company, if the true value of the entity is less than the market is willing to pay for it, you may not be able to generate positive returns over time.
Check Eagle Ownership Details
Eagle Stock Price Odds Analysis
Based on a normal probability distribution, the odds of Eagle Pharmaceuticals jumping above the current price in 90 days from now is about 91.97%. The Eagle Pharmaceuticals probability density function shows the probability of Eagle Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.4131 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Eagle Pharmaceuticals will likely underperform. Additionally, eagle Pharmaceuticals has an alpha of 0.1, implying that it can generate a 0.1 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Eagle Pharmaceuticals to move above the current price in 90 days from now is about 91.97 (This Eagle Pharmaceuticals probability density function shows the probability of Eagle Stock to fall within a particular range of prices over 90 days) .
Eagle Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Eagle Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eagle Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eagle Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Acadian Asset Management Llc | 2023-12-31 | 287.6 K | |
| Dimensional Fund Advisors, Inc. | 2023-12-31 | 246.5 K | |
| J. Goldman & Co Lp | 2023-12-31 | 246.4 K | |
| Geode Capital Management, Llc | 2023-12-31 | 225.3 K | |
| State Street Corporation | 2023-12-31 | 222.6 K | |
| Two Sigma Advisers, Llc | 2023-12-31 | 222 K | |
| Assenagon Asset Management Sa | 2023-12-31 | 217.7 K | |
| Two Sigma Investments Llc | 2023-12-31 | 207.6 K | |
| Bank Of America Corp | 2023-12-31 | 187 K | |
| Blackrock Inc | 2023-12-31 | 984.9 K | |
| Hhg Plc | 2023-12-31 | 775.5 K |
Eagle Pharmaceuticals Historical Income Statement
Eagle Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Eagle's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eagle Pharmaceuticals revenue and expense. Eagle Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Eagle Pharmaceuticals' Income Before Tax is fairly stable compared to the past year. Total Other Income Expense Net is likely to rise to about 9.6 M in 2024, whereas Research Development is likely to drop slightly above 32.8 M in 2024. View More FundamentalsEagle Stock Against Markets
Picking the right benchmark for Eagle Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Eagle Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Eagle Pharmaceuticals is critical whether you are bullish or bearish towards Eagle Pharmaceuticals at a given time. Please also check how Eagle Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eagle Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Eagle Pharmaceuticals Corporate Directors
Eagle Pharmaceuticals corporate directors refer to members of an Eagle Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Eagle Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eagle Pharmaceuticals' board members must vote for the resolution. The Eagle Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Sander Flaum | Independent Director | Profile | |
| David Pernock | Director | Profile | |
| Edward Kay | Director | Profile | |
| Douglas Braunstein | Director | Profile |
How to buy Eagle Stock?
Before investing in Eagle Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Eagle Pharmaceuticals. To buy Eagle Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Eagle Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Eagle Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Eagle Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Eagle Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Eagle Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.
Already Invested in Eagle Pharmaceuticals?
The danger of trading Eagle Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eagle Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eagle Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eagle Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eagle Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eagle Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eagle Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eagle Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eagle Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Eagle Stock please use our How to Invest in Eagle Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for Eagle Stock analysis
When running Eagle Pharmaceuticals' price analysis, check to measure Eagle Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eagle Pharmaceuticals is operating at the current time. Most of Eagle Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eagle Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eagle Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eagle Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Eagle Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eagle Pharmaceuticals. If investors know Eagle will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eagle Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.87) | Earnings Share 0.85 | Revenue Per Share 19.684 | Quarterly Revenue Growth (0.13) | Return On Assets 0.0663 |
The market value of Eagle Pharmaceuticals is measured differently than its book value, which is the value of Eagle that is recorded on the company's balance sheet. Investors also form their own opinion of Eagle Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eagle Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eagle Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eagle Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eagle Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eagle Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eagle Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.